Pank-003 Cell
Solid Tumors, Adult
Shenzhen Celconta Life Science Co., Ltd.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
35 Active assets in the Solid Tumors, Adult cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LEUPROLIDE Eli Lilly and Company | Phase 1/2 | CC |
Letrozole Eli Lilly and Company | Phase 1/2 | CC |
Ribociclib Eli Lilly and Company | Phase 1/2 | CC |
Zoladex Eli Lilly and Company | Phase 1/2 | CC |
Epirubicin Tango Therapeutics, Inc. | Phase 1/2 | CC |
View all 38 →
Same molecule, other indications
Pank-003 Cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →